CTMX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:01):

Stats
Today's Volume	177 588
Average Volume	929 246
Market Cap	109.37M
EPS	$0 ( 2024-03-11 )
Next earnings date	( $-0.0400 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-161.50
ATR14	$0.00400 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Mccarthy Sean A.	Buy	109 768	Common Stock
2024-03-26	Mccarthy Sean A.	Sell	109 768	Stock Option (Right to Buy)
2024-03-20	Su Zhen	Buy	76 000	Stock Option (Right to Buy)
2024-03-20	Su Zhen	Buy	0
2024-03-19	Rowland Lloyd A	Sell	5 268	Common Stock

INSIDER POWER
64.83
Last 98 transactions
Buy: 4 891 928 \| Sell: 1 103 909

Volume Correlation

Long: 0.16 (neutral)

Short: 0.88 (strong)

Signal:(63.588) Same movement expected

CytomX Therapeutics Inc Correlation

10 Most Positive Correlations
GURE	0.925
EYEG	0.922
DIBS	0.919
SWVL	0.918
EIGR	0.917
JOAN	0.917
AFIB	0.916
LPSN	0.913
QRTEA	0.912
RUBY	0.911

10 Most Negative Correlations
SGEN	-0.906
GETVV	-0.903
STAY	-0.894
PUCKU	-0.887
TVTY	-0.886
CCRC	-0.886
DSPG	-0.884
ALTR	-0.875
SNCR	-0.875
MTEK	-0.873

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CytomX Therapeutics Inc Correlation - Currency/Commodity

-0.19
( neutral )

0.00
( neutral )

0.07
( neutral )

CytomX Therapeutics Inc Financials

Annual	2023
Revenue:	$101.21M
Gross Profit:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2023
Revenue:	$101.21M
Gross Profit:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2022
Revenue:	$53.16M
Gross Profit:	$47.31M (88.98 %)
EPS:	$-1.480

FY	2021
Revenue:	$69.57M
Gross Profit:	$69.57M (100.00 %)
EPS:	$-1.300

Financial Reports:

No articles found.

CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.